188 related articles for article (PubMed ID: 14648736)
1. Matrix metalloproteinase 2 and 9 activity in patients with colorectal cancer liver metastasis.
Waas ET; Wobbes T; Lomme RM; DeGroot J; Ruers T; Hendriks T
Br J Surg; 2003 Dec; 90(12):1556-64. PubMed ID: 14648736
[TBL] [Abstract][Full Text] [Related]
2. Matrix metalloproteinase-2 and -9 in bile as a marker of liver metastasis in colorectal cancer.
Okada N; Ishida H; Murata N; Hashimoto D; Seyama Y; Kubota S
Biochem Biophys Res Commun; 2001 Oct; 288(1):212-6. PubMed ID: 11594775
[TBL] [Abstract][Full Text] [Related]
3. Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging.
Baker EA; Bergin FG; Leaper DJ
Br J Surg; 2000 Sep; 87(9):1215-21. PubMed ID: 10971431
[TBL] [Abstract][Full Text] [Related]
4. Matrix metalloproteinase-9,-3 and tissue inhibitor of matrix metalloproteinase-1 in colorectal cancer: relationship to clinicopathological variables.
Işlekel H; Oktay G; Terzi C; Canda AE; Füzün M; Küpelioğlu A
Cell Biochem Funct; 2007; 25(4):433-41. PubMed ID: 16615041
[TBL] [Abstract][Full Text] [Related]
5. Measuring gelatinase activity in colorectal cancer.
Baker EA; Leaper DJ
Eur J Surg Oncol; 2002 Feb; 28(1):24-9. PubMed ID: 11869009
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological significance of the gene expression of matrix metalloproteinases and reversion-inducing cysteine-rich protein with Kazal motifs in patients with colorectal cancer: MMP-2 gene expression is a useful predictor of liver metastasis from colorectal cancer.
Oshima T; Kunisaki C; Yoshihara K; Yamada R; Yamamoto N; Sato T; Makino H; Yamagishi S; Nagano Y; Fujii S; Shiozawa M; Akaike M; Wada N; Rino Y; Masuda M; Tanaka K; Imada T
Oncol Rep; 2008 May; 19(5):1285-91. PubMed ID: 18425389
[TBL] [Abstract][Full Text] [Related]
7. Activation of MMP-2 and MMP-9 in patients with oral squamous cell carcinoma.
Patel BP; Shah PM; Rawal UM; Desai AA; Shah SV; Rawal RM; Patel PS
J Surg Oncol; 2005 May; 90(2):81-8. PubMed ID: 15844188
[TBL] [Abstract][Full Text] [Related]
8. Circulating gelatinases and tissue inhibitor of metalloproteinase-1 in colorectal cancer metastatic liver disease.
Waas ET; Wobbes T; Ruers T; Lomme RM; Hendriks T
Eur J Surg Oncol; 2006 Sep; 32(7):756-63. PubMed ID: 16650961
[TBL] [Abstract][Full Text] [Related]
9. Increased activity of matrix metalloproteinase 2 and 9 after hepatic radiofrequency ablation.
Frich L; Bjørnland K; Pettersen S; Clausen OP; Gladhaug IP
J Surg Res; 2006 Oct; 135(2):297-304. PubMed ID: 16934296
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of MMP-2 and MMP-9 in patients with oral cancer.
Patel BP; Shah SV; Shukla SN; Shah PM; Patel PS
Head Neck; 2007 Jun; 29(6):564-72. PubMed ID: 17252594
[TBL] [Abstract][Full Text] [Related]
11. Comparison of matrix metalloproteinase expression between primary tumors with or without liver metastasis in pancreatic and colorectal carcinomas.
Matsuyama Y; Takao S; Aikou T
J Surg Oncol; 2002 Jun; 80(2):105-10. PubMed ID: 12173379
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of matrix metalloproteinase 2 and 9 in breast cancer.
Shah FD; Shukla SN; Shah PM; Shukla HK; Patel PS
Indian J Cancer; 2009; 46(3):194-202. PubMed ID: 19574670
[TBL] [Abstract][Full Text] [Related]
13. Type IV collagenase (matrix metalloproteinase-2 and -9) in prostate cancer.
Zhang L; Shi J; Feng J; Klocker H; Lee C; Zhang J
Prostate Cancer Prostatic Dis; 2004; 7(4):327-32. PubMed ID: 15356679
[TBL] [Abstract][Full Text] [Related]
14. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma.
Nikkola J; Vihinen P; Vuoristo MS; Kellokumpu-Lehtinen P; Kähäri VM; Pyrhönen S
Clin Cancer Res; 2005 Jul; 11(14):5158-66. PubMed ID: 16033831
[TBL] [Abstract][Full Text] [Related]
15. Association of a high activity of matrix metalloproteinase-9 to low levels of tissue inhibitors of metalloproteinase-1 and -3 in human hepatitis B-viral hepatoma cells.
Kim JR; Kim CH
Int J Biochem Cell Biol; 2004 Nov; 36(11):2293-306. PubMed ID: 15313474
[TBL] [Abstract][Full Text] [Related]
16. MMP-2 expression in uveal melanoma: differential activation status dictated by the cellular environment.
Bérubé M; Deschambeault A; Boucher M; Germain L; Petitclerc E; Guérin SL
Mol Vis; 2005 Dec; 11():1101-11. PubMed ID: 16379022
[TBL] [Abstract][Full Text] [Related]
17. Invasion front-specific overexpression of tissue inhibitor of metalloproteinase-1 in liver metastases from colorectal cancer.
Kahlert C; Bandapalli OR; Schirmacher P; Weitz J; Brand K
Anticancer Res; 2008; 28(3A):1459-65. PubMed ID: 18630499
[TBL] [Abstract][Full Text] [Related]
18. Increased matrix metalloproteinase-2 and membrane type 1 matrix metalloproteinase activity and expression in heterotopically transplanted murine tracheas.
Inaki N; Tsunezuka Y; Kawakami K; Sato H; Takino T; Oda M; Watanabe G
J Heart Lung Transplant; 2004 Feb; 23(2):218-27. PubMed ID: 14761770
[TBL] [Abstract][Full Text] [Related]
19. Matrix metalloproteinase-7 expression in colorectal cancer liver metastases: evidence for involvement of MMP-7 activation in human cancer metastases.
Zeng ZS; Shu WP; Cohen AM; Guillem JG
Clin Cancer Res; 2002 Jan; 8(1):144-8. PubMed ID: 11801551
[TBL] [Abstract][Full Text] [Related]
20. Etodolac, a selective cyclooxygenase-2 inhibitor, inhibits liver metastasis of colorectal cancer cells via the suppression of MMP-9 activity.
Ishizaki T; Katsumata K; Tsuchida A; Wada T; Mori Y; Hisada M; Kawakita H; Aoki T
Int J Mol Med; 2006 Feb; 17(2):357-62. PubMed ID: 16391837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
